On June 6, 2016, a motion for authority to sell assets of the estates pursuant to section 363 of the Bankruptcy Code was filed in the bankruptcy case of NephroGenex, Inc. and its affiliates.
The filing was assigned docket number 81 and is described on the court’s official docket as follows:
Motion to Approve (Debtor’s Motion for Order Pursuant to Sections 105(a), 363 and 554(a) of the Bankruptcy Code and Bankruptcy Rule 2002 Authorizing and Approving Procedures for the Sale or Abandonment of De Minimis Assets Free and Clear of Liens, Claims, Interests and Encumbrances). Filed by NephroGenex, Inc.. Hearing scheduled for 6/27/2016 at 03:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. Objections due by 6/20/2016. (Attachments: # (1) Notice of Motion # (2) Proposed Form of Order with Exhibits A and B) (Hurst, David)
NephroGenex, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on April 30, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-11074. The bankruptcy case is currently assigned to United States Bankruptcy Judge Judge Not Yet Assigned. The law firm of Cole, Schotz, Meisel, Forman & Leonard, P.A. is acting as lead bankruptcy counsel to NephroGenex, Inc. in the bankruptcy case.